anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Caregivers who consent to participate, complete a baseline survey, and are assigned to the intervention arm will receive a Disaster PrepWise-Caregiver program from a trained interventionist and receive a completed household emergency management plan. Control participants will complete follow-up surveys at 3 and 6 months, similar to intervention participants.
Varenicline tablets contain varenicline (as the tartrate salt), which is a partial nicotinic agonist selective for α4β2 nicotinic acetylcholine receptor subtypes.  
Varenicline, as the tartrate salt, is a powder which is a white to off-white to slightly yellow solid with the following chemical name: 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3- h][3]benzazepine,(2R,3R)-2,3-dihydroxybutanedioate (1:1). It is highly soluble in water. Varenicline tartrate has a molecular weight of 361.35 Daltons, and a molecular formula of C13H13N3 • C4H6O6. The chemical structure is:

  


Varenicline tablets are supplied for oral administration in two strengths: a 0.5 mg (white to off-white, capsule shaped film coated tablets, debossed with “1 C” on one side and plain on other side.) and 1 mg (light blue, capsule shaped film-coated tablets, debossed with “2 C” on one side and plain on other side.) Each 0.5 mg varenicline tablet contains 0.85 mg of varenicline tartrate equivalent to 0.5 mg of varenicline free base; each 1 mg varenicline tablet contains 1.71 mg of varenicline tartrate equivalent to 1 mg of varenicline free base. The following inactive ingredients are included in the tablets: silicified microcrystalline cellulose, maltodextrin, croscarmellose sodium, stearic acid, hypromellose, titanium dioxide, macrogol/polyethylene glycol, triacetin. In addition to these, the 1 mg tablet film coating includes FD&C blue #2/indigo carmine aluminum lake.
Humans use cannabinoid drugs to alleviate pain. As cannabis and cannabinoids are legalized in the United States for medicinal and recreational use, it has become critical to determine the potential utilities and harms of cannabinoid drugs in individuals living with chronic pain. Here, we tested the effects of repeated ∆9-tetrahydrocannabinol (THC) vapor inhalation on thermal nociception and mechanical sensitivity, in adult male and female Wistar rats using a chronic inflammatory pain model (ie, treated with complete Freund's adjuvant [CFA]). We report that repeated THC vapor inhalation rescues thermal hyperalgesia in males and females treated with CFA and also reduces mechanical hypersensitivity in CFA males but not females. Many of the antihyperalgesic effects of chronic THC vapor were still observable 24 hours after cessation of the last THC exposure. We also report plasma levels of THC and its major metabolites, some of which are cannabinoid type-1 receptor agonists, after the first and tenth days of THC vapor inhalation. Finally, we report that systemic administration of the cannabinoid type-1 receptor inverse agonist AM251 (1 mg/kg, I.P.) blocks the antihyperalgesic effects of THC vapor in males and females. These data provide a foundation for future work that will explore the cells and circuits underlying the antihyperalgesic effects of THC vapor inhalation in individuals with chronic inflammatory pain. PERSPECTIVE: Cannabinoids are thought to have potential utility in the treatment of chronic pain, but few animal studies have tested the effects of chronic THC or cannabis in animal models of chronic pain. We tested the effects of repeated THC vapor inhalation on chronic pain-related outcomes in male and female animals.
Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of primary site undergo neck dissection within 4 weeks.
<P>PROBLEM TO BE SOLVED: To obtain skin bleaching composition, to provide a use of the composition as a cosmetic, and a method for suppressing melanogenesis using the composition.  <P>SOLUTION: The skin bleaching composition contains a plant extract selected from those of asparagus, black cohosh or their mixture, wherein the extract is obtained by sequentially exposing the plant or its part to two or more solvents having varying solvent strengths. The root and seedling portions of the plant can be separately used to obtain the extract. The composition can be topically applied to human skin and can further contain one or more cosmetically acceptable ingredients. The method for suppressing the melanogenesis includes topically applying to the skin the composition comprising the extract of plant selected from asparagus, black cohosh or their mixture obtained by sequentially exposing the plants to two or more solvents having varying solvent strengths.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE:To enable iterative use by bonding an antibody by covalent bonding to the surface of glass having the activated surface. CONSTITUTION:The immobilized antibody is formed by bonding the antibody by covalent bonding to the surface of the glass having the activated surface. The glass to be used as a carrier for immobilization may be any shape such as bead or fiber shape. The activation of the glass surface is executed by introducing the group of reaction activity, for example, amino group, thiol group, etc., to the surface of the glass. IgG, etc., formed by immunizing the antigen to be measured to a warm-blooded animal is used as the antibody. As to the method of bonding the glass and the antibody, the bonding of the glass and Fab' is executed by using a maleimide crosslinking reagent in the case of using, for example, glass having the amino group on the surface.
The present invention belongs to the technical field of biochemical separation and purification, and relates to production technology for separating and purifying oligomer pro-anthocyanidin and ursolic acid from hawthorns. The present invention adopts ethanol for extraction from fresh hawthorns or dried hawthorns. Extractives are refrigerated after ethanol removal. The extractives are centrifugally separated. Supernatant fluid is sprayed on polyamide columns, washed, eluted and dried by spray in order to obtain dry pro-anthocyanidin powder. Sediments are washed by water, and are dried in order to obtain ursolic acid products. The products can be made into tablets, capsules, chewable tablets, and oral medicine liquid, and is health food for inflammation, antibiosis, diabetes resistance, canker resistance, blood fat decrease, etc. The products can be made into medicine by further purification.
Participants assigned to Cohort 3 group A and group C will receive JNJ-42847922 40 mg, 3 hours after completing dinner. Participants in group B will receive JNJ-42847922 40 mg, 3 hours after completing dinner in Period 1, followed by at least 7 days washout period, further followed by JNJ-42847922 40 mg, immediately after completing dinner.
This research is a self-controlled study. One injected arm of the patient will be assigned to the intervention group and the other arm to the control group. İn the experimental arm, the research nurse working in the Coronary Intensive Care unit (CICU) applied 5-6 drops of HP oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied. The assessment of ecchymosis and pain at the injection site was performed by two other investigators at the 48th hour of the injection (Single blind).
Iptacopan was not genotoxic or mutagenic in a battery of in vitro and in vivo assays.

Carcinogenicity studies conducted with oral administration of iptacopan in RasH2 transgenic mice with doses up to 1,000 mg/kg/day for 6 months and in rats with doses up to 750 mg/kg/day for 2 years did not identify any carcinogenic potential. The highest exposure to iptacopan in rats corresponds to approximately 9-times the MRHD based on AUC.

In a fertility study in male rats, iptacopan did not adversely impact fertility up to the highest tested dose of 750 mg/kg/day, which corresponds to 4-times the MRHD based on AUC. Reversible effects on the male reproductive system (testicular tubular degeneration and cellular debris in epididymis) were observed in repeat-dose toxicity studies with oral administration in dogs at doses ≥ 2-times the MRHD based on AUC, with no clear effects on sperm numbers, morphology, or motility. In a fertility and early embryonic developmental study in female rats, oral administration of iptacopan caused increased pre- and post-implantation losses when given at the highest dose of 1,000 mg/kg/day orally, which corresponds to approximately 11-times the MRHD based on AUC.
This study is a randomized, double-blinded, placebo controlled Phase III study to evaluate the immunogenicity and the safety of GSK Bio influenza vaccine (Fluarix) administered intramuscularly in healthy adults aged 18 to 64 years. Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk. Following vaccination, seroprotective antibody titers are achieved in a high proportion of vaccinated subjects. GlaxoSmithKline Biologicals (GSK Bio) has been marketing an inactivated influenza split vaccine (Fluarix®) since 1992. More than 126 million doses have been distributed and the vaccine is registered in 78 countries. It has been well tolerated and has proven to be highly immunogenic when injected by the intramuscular route.
PURPOSE:To easily remove tartar and nicotine which have been difficult to remove by tooth brushing without damaging a tooth and the gum by injecting an enzyme to the groove of a scaler, fitting the scaler to the teeth of the upper and lower jaws, and fixing the enzyme. CONSTITUTION:A tooth form 1 with a groove 2 covering a tooth 5 and the gum which form encloses the whole tooth 5 is formed. The tooth form l is formed into a row of teeth having the groove 2 with a depth covering the tooth 5 and the gum between the front wall and the rear wall, and the front wall and rear wall end parts are extended to provide collars 3, respectively. A paste enzyme such as sordes decomposing enzyme is injected into the groove 2, and this tooth form 1 is fitted to the upper and lower jaws, and the enzyme is fixed and applied to the tooth 5 and the gum. The collars 3 are longitudinally provided to prevent the leakage of the enzyme, and the tooth form 1 is supported to the gum by the longitudinal collars 3. After the enzyme penetrates the tartar between the tooth 5 and the gum, the tooth form is removed followed by wiping, whereby the tartar is removed.
Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
The invention relates to fragrance precursors. In particular, the invention relates to the use of several classes of compounds which can act as fragrance precursors e.g. in cosmetic products such as deodorants and antiperspirants and in laundry products such as detergents and fabric softeners. These compounds are normally odorless or nearly so, but upon contacting the skin as for example, in skin care compositions or in personal care compositions, produce fragrances. The compounds also produce fragrances when used in the presence of lipases, e.g. as used in (laundry) detergents, thus providing a prolongation of the fabric scenting effect.    The compounds under consideration are compounds of the formula (see fig. I) The substituents are defined in the specification.
In this RCT the investigators are comparing 2 strategies to improve bone health to usual care. Strategy 1 - Patient and physician-specific written educational material. Pilot-tested customized written educational material about bone health for men on ADT will be used for this study. A customized letter will be prepared for the patient's primary care physician, with specific advice and recommendations for the targeted strategies. Both pamphlet and letter will include a list of additional resources. Strategy 2 - patient written material and a bone health care coordinator (BHCC). The same written patient material as in strategy 1 will be used, along with a BHCC who will follow the approach of successful studies and contact the patient by phone or arrange an in-person visit at the hospital if preferred by the patient. The BHCC will also encourage the patient to pursue a bone mineral density test (BMD) with their physician and adopt bone-appropriate diet, lifestyle, and supplement intake recommendations, and will follow up with the patient at least twice over the next 3 months to facilitate behavioural changes and BMD ordering. Counselling sessions are short, typically \<15 min. The BHCC will also contact the patient's physician to help facilitate BMD testing. Time points in the study are baseline, 3-month follow up, and 6-month follow up.

Control group The control group consists of a wait-list control for 6 months, during which no specific recommendations or interventions will be made by the study team. Prostate Cancer (PC) clinicians can still provide usual care. At the end of 6 months, control group participants will be referred to the Osteoporosis Clinic at the University Health Network.
Patients will receive intermittent dosing of hormone therapy with commercially supplied luteinizing hormone-releasing hormone (LHRH) agonist and anti-androgen to be chosen by physician per standard of care. Exisulind will be started 3 months prior to the end of the second cycle of hormone therapy. Patients will continue treatment with Exisulind beyond the completion of the second cycle of hormone therapy until they meet criteria for discontinuation.
OBJECTIVE: We aimed to determine the demographics and clinical presentation of young persons with epilepsy (YPE) 18-years and older who have not transitioned to adult health care systems (AHCS) and to investigate the number of neurology-related hospital encounters in this population before and after attaining adulthood.
METHODS: We conducted a single-site retrospective cohort study at Dayton Children's Hospital (DCH) between 12/01/2021 and 5/31/2022. We included epilepsy patients 18-years and older. Patient demographics, insurance, number of hospitalizations and Emergency Department (ED) visits before and after 18 years of age, clinical presentation, and comorbidities were collected.
RESULTS: 251 patient charts were reviewed. The median age was 20.9 years. The most common comorbidities were intellectual disability (36 %) and psychiatric illnesses (59 %). The majority had generalized epilepsy (52 %) and tonic-clonic seizures (56 %). 58 % of the patients had infrequent seizures in the past year. Documentation of transition to AHCS discussion occurred in only 3 % of patients before age 18 compared to 35 % of patients after age 18. There was a decrease in 30 % for ED visits and 15 % for neurology related hospitalizations after the age of 18.
CONCLUSION: YPE 18-years of age and older who were managed by a pediatric neurologist at DCH had significant co-morbidities. However, they were clinically stable and rarely required admission to the hospital. Most of them did not have documentation about transition discussions. At DCH, YPE who have not transitioned to AHCS are clinically stable and well managed.
In the experimental group, the participants will receive clinic-based rehabilitation first. After a 3-week washout period, the participants will receive home-based rehabilitation.
NEW MATERIAL:A compound shown by the formulaI(R1 is H, lower alyl, or aryl; R2 is H or R2 and R1 are linked to carbon chain in cyclic state; X is halogen). EXAMPLE:4-Chloromethyl-1,3-dioxolen-2-one. USE:Useful especially as a modifying agent for a prodrug of a medicine. PROCESS:A compound shown by the formula II is reacted with preferably 0.8- 1.2mol halogenating agent (e.g., Cl, Br, etc.) at room temperature or usually under conditions to produce a radical under heating, to give a compound shown by the formulaI. Ultraviolet light is irradiated during the reaction, or a free- radical initiator such as alpha,alpha'-azobisisobutyronitrile, etc. is added to the reaction system, so that the reaction is preferably promoted. An ester and an ether derived from the compound shown by the formulaIare stable in a neutral medium, but it is easily hydrolyzed under common alkali hydrolyzing conditions, so it is useful as a reagent for introducing a protecting group in chemical reactions.
Pharmaceutical compositions for the treatment of gastrointestinal peptic disorders comprise a non-toxic, dextrorotatory, pantothenyl group-containing compound consisting of coenzyme A or a precursor of coenzyme A containing the potentially biologically active pantothenyl moiety, said precursor being synthesizable by the body to coenzyme A, and an anticholinergic compound and an antacid.  Specified coenzyme A precursors are d-pantothenyl alcohol, d-pantothenic acid and non-toxic salts thereof (e.g. the calcium, potassium and sodium salts), pantethine and pantetheine; specified anticholinergics include methyl or ethyl substituted scopolamine salts, belladonna alkaloids, propantheline bromide, methantheline bromide, ambutonium bromide, aminopentamide sulphate, dibutoline sulphate, dicyclomine hydrochloride, procyclidine hydrochloride, tricyclamol chloride, tridihexethyl iodide and/or chloride, oxyphencyclimine hydrochloride, isopropamide iodide, mepenzolate methylbromide, valethamate bromide, and oxyphenonium bromide; antacids specified are calcium carbonate, magnesium trisilicate, magnesium carbonate, aluminium hydroxide gel, magnesium oxide, magnesium hydroxide, glycine, dihydroxy aluminium aminoacetate, calcium caseinate, alkali metal bicarbonates, monocalcium phosphate, sodium carboxymethylcellulose, aluminium phosphate gel, bismuth subcarbonate, disodium phosphate, tricalcium phosphate, gastric mucin and non-toxic anion exchange resins.  The compositions may optionally contain antihaemorrhagic and coagulant compounds such as n-butyl alcohol, thrombin, gelatin, Vitamin K, carboxymethylcellulose and methylcellulose; local anaesthetics such as procaine hydrochloride, benzocaine and benzonatate; digestive enzymes such as trypsin and chymotrypsin, and cellulose digesting enzymes such as cellulase; general sedatives such as barbiturates (many examples are given), 3-O-tolyl-4 (3H)-quinazolone hydrochloride, phenothiazine compounds, meprobamate and its derivatives, and rauwolfia alkaloids; nutrients such as defatted milk solids, and vegetable or animal protein or fat.  The compositions may take the form of powders, tablets or liquids, and may be administered orally or parenterally.  Specification 744,223 is referred to.
Background: The increasing prevalence of child and adolescent overweight and obesity (CAOAO) in Beijing poses significant health and economic challenges. This study assesses the potential health and economic outcomes of implementing specific interventions to address CAOAO in Beijing. Methods: A deterministic Markov cohort model was used to estimate the impact of five interventions from 2025 to 2115: restrictions on unhealthy food marketing to children, mandatory front of package labeling (FOPL), family-based nutrition and exercise education, school-based nutritional health education, and nutritional counseling in primary healthcare. The model evaluated societal costs, healthcare savings, wages, and economic productivity in adulthood, calculating the return on investment (ROI) for each intervention and their combined effect. Result: Without intervention, Beijing is projected to experience a loss of 13.4 million disability-adjusted life years (DALYs) due to CAOAO. The health and economic impact of childhood obesity in Beijing is projected to be CNY 14.6 trillion (USD 2.1 trillion), or a lifetime loss of CNY 6.8 million (USD 0.96 million) per affected child, exceeding the sum of Beijing's GDP from 2021 to 2023. Restrictions on unhealthy food marketing to children and nutrition counseling in primary healthcare are projected to yield the highest returns, with benefits accruing within one year of implementation. Owing to the substantial upfront costs, including personnel, materials, and training, school-based and family-based interventions require a longer time horizon to realize significant health and economic benefits. Conclusions: Effective management of CAOAO in Beijing demands a multifaceted approach. The combination of restrictions on unhealthy food marketing to children, mandatory front of package labeling, nutrition counseling in primary healthcare, school-based intervention, and family-based intervention presents the most substantial health and economic returns. This comprehensive strategy aligns with global best practices and addresses the unique challenges faced by Beijing in combating childhood obesity.
After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months.
Provided are a film-forming composition suitable for hard capsules and a method for preparing the same composition. The hard capsules prepared have improved mechanical properties as well as water-soluble, biodegradable and edible properties. The hard capsules prepared are also nontoxic to human body and do not cause environment pollution. The film-forming composition suitable for hard capsules comprises 7-12 wt.% of starch, 1-6 wt.% of a plasticizer, 0.7-3 wt.% of a gelating agent, and 79-91.3 wt.% of water, wherein the starch contains 10-30% amylose; the starch is selected from potato starch, chestnut starch and mung bean starch; the plasticizer is selected from glycerol, sorbitol, PEG(polyethylene glycerol), mannitol and maltitol; and the gelating agent is selected from carrageenan, agar gum, pectin, alginate, gum arabic, xanthan gum, gellan and a mixture thereof. The method for preparing the film-forming composition suitable for hard capsules comprises the steps of: (a) adding 1-6 wt.% of the plasticizer into 79-91 wt.% of water and stirring the mixture at 25-60 deg. C; (b) adding 0.7-3 wt.% of the gelating agent into the mixture of step (a) and stirring the mixture at 45-55 deg. C; and (c) adding 7-12 wt.% of starch into the mixture of step (b), increasing the temperature of the mixture up to 85-95 deg. C and stirring the mixture at this temperature.